Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Description

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Conditions

Neoplasms

Talk to us

Study Overview

On this page

Study Details

Study overview

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Condition
Neoplasms
Intervention / Treatment

-

Contacts and Locations

Atlanta

Emory University School of Medicine, Atlanta, Georgia, United States, 30322

Baltimore

ADP Investigational Site, Baltimore, Maryland, United States, 21201

Bethesda

National Cancer Institute - Center for Cancer Research, Bethesda, Maryland, United States, 20892

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

Saint Louis

Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States, 63110

New York

Memorial Sloan Kettering Cancer Center - New York, New York, New York, United States, 10065

Durham

Duke University Medical Center, Durham, North Carolina, United States, 27710

Portland

Oregon Health and Science University, Portland, Oregon, United States, 97239

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Pittsburgh

University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania, United States, 15232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants who have received at least one dose of ADP adoptive cell therapy agent.
  • * Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
  • * Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
  • * Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • * The investigator is responsible for review of medical history.
  • * Capable of giving signed informed consent.

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Adaptimmune,

Adaptimmune, STUDY_DIRECTOR, Adaptimmune

Study Record Dates

2032-04-01